Literature DB >> 28131894

GABA and glutamate levels correlate with MTR and clinical disability: Insights from multiple sclerosis.

Julia C Nantes1, Sébastien Proulx2, Jidan Zhong1, Scott A Holmes1, Sridar Narayanan3, Robert A Brown4, Richard D Hoge4, Lisa Koski1.   

Abstract

Converging areas of research have implicated glutamate and γ-aminobutyric acid (GABA) as key players in neuronal signalling and other central functions. Further research is needed, however, to identify microstructural and behavioral links to regional variability in levels of these neurometabolites, particularly in the presence of demyelinating disease. Thus, we sought to investigate the extent to which regional glutamate and GABA levels are related to a neuroimaging marker of microstructural damage and to motor and cognitive performance. Twenty-one healthy volunteers and 47 people with multiple sclerosis (all right-handed) participated in this study. Motor and cognitive abilities were assessed with standard tests used in the study of multiple sclerosis. Proton magnetic resonance spectroscopy data were acquired from sensorimotor and parietal regions of the brains' left cerebral hemisphere using a MEGA-PRESS sequence. Our analysis protocol for the spectroscopy data was designed to account for confounding factors that could contaminate the measurement of neurometabolite levels due to disease, such as the macromolecule signal, partial volume effects, and relaxation effects. Glutamate levels in both regions of interest were lower in people with multiple sclerosis. In the sensorimotor (though not the parietal) region, GABA concentration was higher in the multiple sclerosis group compared to controls. Lower magnetization transfer ratio within grey and white matter regions from which spectroscopy data were acquired was linked to neurometabolite levels. When adjusting for age, normalized brain volume, MTR, total N-acetylaspartate level, and glutamate level, significant relationships were found between lower sensorimotor GABA level and worse performance on several tests, including one of upper limb motor function. This work highlights important methodological considerations relevant to analysis of spectroscopy data, particularly in the afflicted human brain. These findings support that regional neurotransmitter levels are linked to local microstructural integrity and specific behavioral abilities that can be affected in diseases such as multiple sclerosis.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GABA; Glutamate; Magnetization transfer ratio; Multiple sclerosis; Myelin; Proton magnetic resonance spectroscopy

Mesh:

Substances:

Year:  2017        PMID: 28131894     DOI: 10.1016/j.neuroimage.2017.01.033

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  13 in total

1.  Oligodendrocytes Support Neuronal Glutamatergic Transmission via Expression of Glutamine Synthetase.

Authors:  Wendy Xin; Yevgeniya A Mironova; Hui Shen; Rosa A M Marino; Ari Waisman; Wouter H Lamers; Dwight E Bergles; Antonello Bonci
Journal:  Cell Rep       Date:  2019-05-21       Impact factor: 9.423

2.  Altered hippocampal GABA and glutamate levels and uncoupling from functional connectivity in multiple sclerosis.

Authors:  Fei Gao; Xuntao Yin; Richard A E Edden; Alan C Evans; Junhai Xu; Guanmei Cao; Honghao Li; Muwei Li; Bin Zhao; Jian Wang; Guangbin Wang
Journal:  Hippocampus       Date:  2018-11       Impact factor: 3.899

3.  Neural correlates of symptom severity in obsessive-compulsive disorder using magnetization transfer and diffusion tensor imaging.

Authors:  Suzan Maleki; Yann Chye; Xiaoliu Zhang; Linden Parkes; Samuel R Chamberlain; Leonardo F Fontenelle; Leah Braganza; George Youssef; Valentina Lorenzetti; Ben J Harrison; Murat Yücel; Chao Suo
Journal:  Psychiatry Res Neuroimaging       Date:  2020-02-11       Impact factor: 2.376

Review 4.  The potential roles of amino acids and their major derivatives in the management of multiple sclerosis.

Authors:  Somayeh Pashaei; Reza Yarani; Pantea Mohammadi; Mohammad Sajad Emami Aleagha
Journal:  Amino Acids       Date:  2022-04-26       Impact factor: 3.520

5.  A systems medicine approach reveals disordered immune system and lipid metabolism in multiple sclerosis patients.

Authors:  M Pazhouhandeh; M-A Sahraian; S D Siadat; A Fateh; F Vaziri; F Tabrizi; F Ajorloo; A K Arshadi; E Fatemi; S Piri Gavgani; F Mahboudi; F Rahimi Jamnani
Journal:  Clin Exp Immunol       Date:  2018-01-25       Impact factor: 4.330

6.  Reduced GABA levels correlate with cognitive impairment in patients with relapsing-remitting multiple sclerosis.

Authors:  Guanmei Cao; Richard A E Edden; Fei Gao; Hao Li; Tao Gong; Weibo Chen; Xiaohui Liu; Guangbin Wang; Bin Zhao
Journal:  Eur Radiol       Date:  2017-10-06       Impact factor: 5.315

7.  Altered in vivo brain GABA and glutamate levels are associated with multiple sclerosis central fatigue.

Authors:  Jameen Arm; Georg Oeltzschner; Oun Al-Iedani; Rod Lea; Jeannette Lechner-Scott; Saadallah Ramadan
Journal:  Eur J Radiol       Date:  2021-02-24       Impact factor: 3.528

Review 8.  Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker.

Authors:  Kelley M Swanberg; Karl Landheer; David Pitt; Christoph Juchem
Journal:  Front Neurol       Date:  2019-11-15       Impact factor: 4.003

9.  MEGA-PRESS of GABA+: Influences of acquisition parameters.

Authors:  Dinesh K Deelchand; Małgorzata Marjańska; Pierre-Gilles Henry; Melissa Terpstra
Journal:  NMR Biomed       Date:  2019-10-28       Impact factor: 4.044

10.  A Multi-Ligand Imaging Study Exploring GABAergic Receptor Expression and Inflammation in Multiple Sclerosis.

Authors:  Yeona Kang; Sandra Milena Hurtado Rúa; Ulrike W Kaunzner; Jai Perumal; Nancy Nealon; Wenchao Qu; Paresh J Kothari; Timothy Vartanian; Amy Kuceyeski; Susan A Gauthier
Journal:  Mol Imaging Biol       Date:  2020-12       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.